Merkel Cell Carcinoma (MCC) | ApexOnco - Clinical Trials news and analysis

x

“I am very impressed - it has become my go-to platform”

Chief Business Officer

US public biotech company

Click here for more information

Data insights

26 June 2025

TuHura makes its bid for Merkel accelerated approval

The company reckons its immunotherapy could improve on Keytruda.

Subscribe to Merkel Cell Carcinoma (MCC)